Clinical trials for Prostate cancer

147 currently recruiting clinical trials
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT06781983
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Innate Pharma
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Lymphoma Ovarian / Fallopian tubes / Peritoneum cancer #NCT06514651 #2023-507774-41-00
Required disease stage
Metastatic
Required number of previous lines of therapy
1 2 3 or more
1 recruiting site
MabQuest SA
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06507306 #2024-511453-22-00
Partie 1Escalade de dose monothérapie
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other KRAS EGFR KRAS G12C KRAS G12D KRAS non G12C NRAS Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Kumquat Biosciences Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT06253871 #2024-519188-17-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Iambic Therapeutics, Inc
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04777994 #2023-507568-38-00
Escalade de dose (Tumeurs solides)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC
Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT04777994 #2023-507568-38-00
Dose d'expansion cohorte combinaison avec inhibiteur PD-1 tumeurs MSI-H
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC
Phase 1 Prostate cancer #NCT06220864 #2025-520557-36-00
Expansion de dose cancer de la prostate résistant à la castration
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Synnovation Therapeutics, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06220864 #2025-520557-36-00
Expansion de dose pour les tumeurs solides avec des métastases cérébrales
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Synnovation Therapeutics, Inc.
Phase 1 Prostate cancer #NCT06220864 #2025-520557-36-00
Thérapie combinée mCRPC or mCSPC
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Synnovation Therapeutics, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05382559 #2022-501590-39-00
Cohorte combinaison ASP3082 + Cetuximab
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Astellas Pharma Développement mondial, Inc.